Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
- Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
- 03/06/2025
|
89bio to Participate in the Leerink Partners Global Healthcare Conference
- SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website.
- 03/03/2025
|
89bio price target lowered by $8 at H.C. Wainwright, here's why
|
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024; a follow-on offering in the 1Q 2025 resulted in gross proceeds of $287.5 million – SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates.
- 02/27/2025
|
Should You Buy 89BIO (ETNB) After Golden Cross?
- 89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
- 02/20/2025
|
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 02/20/2025
|
Insider Buying Surges in February, Especially in These 6 Stocks
- In January, the number of notable insider purchases was somewhat muted.
- 02/09/2025
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company's common stock to seven new employees (the “Inducement Grants”) on January 31, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/06/2025
|
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 02/03/2025
|
89bio's Pegozafermin Is Now Gaining Momentum
- 89bio's Pegozafermin Is Now Gaining Momentum
- 01/30/2025
|
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 21,671,428 shares of its common stock at a public offering price per share of $8.75 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 6,900,000 shares of its common stock at a public offering price of $8.749. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 4,285,714 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $250.0 million. The offering is expected to close on or about January 30, 2025, subject to the satisfaction of customary closing conditions.
- 01/28/2025
|
Why 89bio Stock Lagged the Market Today
- 89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue.
- 01/28/2025
|
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.
- 01/27/2025
|
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
- 89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 ENTRIGUE study indicated that patients treated with all doses of pegozafermin were able to achieve the primary endpoint with statistical significance. The global severe hypertriglyceridemia treatment market is expected to reach $2.67 billion by 2033.
- 01/13/2025
|
New Strong Sell Stocks for January 7th
- ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
- 01/07/2025
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to one new employee (the “Inducement Grant”) on December 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 12/19/2024
|
New Strong Sell Stocks for November 16th
- CLF, ETNB and HZO have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2024.
- 12/16/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the “Inducement Grants”) on November 25, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/29/2024
|
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
- New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
- 11/15/2024
|
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 11,455,882 shares of its common stock at a public offering price per share of $8.50 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 3,250,000 shares of its common stock at a public offering price of $8.499. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,205,882 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $125.0 million. The offering is expected to close on or about November 14, 2024, subject to the satisfaction of customary closing conditions.
- 11/12/2024
|
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.
- 11/12/2024
|
89bio to Participate in the UBS Global Healthcare Conference
- SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.
- 11/05/2024
|
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
- SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be featured in four poster presentations at the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024 being held November 15 to 19, 2024 in San Diego, California.
- 10/15/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 265,000 shares of the Company's common stock to two new employees (the “Inducement Grants”) on October 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/11/2024
|
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.
- 09/30/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company's common stock to one new employee (the “Inducement Grant”) on September 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/19/2024
|
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company.
- 09/16/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company's common stock to two new employees and 350,000 shares of the Company's common stock to the newly-hired Chief Operating Officer, Francis Sarena (the “Inducement Grants”) on August 5, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/09/2024
|
89bio: Bullish In Light Of Further MOA Being Established By Peer
- 89bio, Inc. has two phase 3 studies underway, known as ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are using pegozafermin to target F2 — F3 and F4 compensated cirrhosis MASH patients respectively. The promise of the two ongoing phase 3 ENLIGHTEN studies is that there was alignment gained with the FDA that each could use an interim analysis endpoint for potential Accelerated Approval. The global non-alcoholic steatohepatitis market is projected to reach $24.26 billion by 2028.
- 08/07/2024
|
89bio Appoints Francis Sarena as Chief Operating Officer
- SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024.
- 08/07/2024
|
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
- –The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients–
- 08/05/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 125,000 shares of the Company's common stock to six new employees (the “Inducement Grants”) on July 9, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/12/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company's common stock to two new employees (the “Inducement Grants”) on June 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/14/2024
|
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
- 89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin has the potential to tap into a large market and has been granted FDA Breakthrough Therapy designation for treating MASH with fibrosis.
- 05/23/2024
|
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
- 05/22/2024
|
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—
- 05/14/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company's common stock to four new employees (the “Inducement Grants”) on May 6, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/10/2024
|
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- –Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients–
- 05/09/2024
|
89bio to Participate in the BofA Securities 2024 Health Care Conference
- SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 2:20 PM PDT and participate in one-on-one investor meetings.
- 05/08/2024
|
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
- 89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/06/2024
|
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH
- Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET
- 05/02/2024
|
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
- 04/17/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company's common stock to eight new employees (the “Inducement Grants”) on April 3, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/05/2024
|
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
- –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with MASH. The PRIME status was supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin in patients with non-cirrhotic MASH with fibrosis (F2-F3) and MASH with compensated cirrhosis (F4).
- 03/27/2024
|
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
- —Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients—
- 03/12/2024
|
Buffett Loads Up on This Stock Again, Plus CEO Insider Buying
- In the wake of a media giant's quarterly report, the Oracle of Omaha is again bolstering his stake in the tracking stocks with some huge insider purchases.
- 03/10/2024
|
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company's common stock to a new employee (the “Inducement Grant”) on March 6, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to this individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/08/2024
|
89bio to Participate in the Leerink Partners Global Biopharma Conference
- SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings.
- 03/05/2024
|
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 03/05/2024
|
89BIO (ETNB) Just Overtook the 200-Day Moving Average
- After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
- 03/05/2024
|
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- – Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively –
- 02/29/2024
|
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings.
- 02/06/2024
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 28,400 shares of the Company's common stock to two new employees (the “Inducement Grants”) on the later of February 2, 2024 and the employee's commencement of employment with the Company (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/05/2024
|
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
- After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
- 01/18/2024
|
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
- The mean of analysts' price targets for 89BIO (ETNB) points to a 168.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 01/10/2024
|
89bio: Despite Peer Trial Setback, Potential Remains In NASH
- 89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMMETRY study of efruxifermin for F4 NASH patients in Q1 of 2024; Success for Akero could mean a boost in value for 89bio. The non-alcoholic steatohepatitis market size is projected to reach $24.26 billion by 2028.
- 12/06/2023
|
89bio's Low Price Presents An Opportunity
- 89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive with excellent phase 2 data and strong financials. 89bio's pegozafermin has shown positive results in reducing fibrosis and liver fat, and there is still potential for FGF21 molecules in the NASH field.
- 10/26/2023
|
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
- SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.
- 10/17/2023
|
Why Shares of 89bio Plummeted on Tuesday
- 89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases.
- 10/10/2023
|
89bio to Participate in the 2023 Cantor Global Healthcare Conference
- SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the 2023 Cantor Global Healthcare Conference, being held in New York, NY on Tuesday, September 26, 2023 at 11:40 AM ET.
- 09/20/2023
|
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held in New York, NY on Monday, September 11, 2023 at 7:00 AM ET.
- 09/05/2023
|
89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic
- Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from the biotechnology company's current share price of US$16.55. The analysts believe 89bio's differentiated investigational therapeutic FGF21 analog pegozafermin (PGZ) has high potential in non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease characterized by inflammation and fibrosis of the liver that can progress to cirrhosis, liver failures, and liver cancer.
- 08/28/2023
|
89bio, Inc.: A Big Bet On NASH
- 89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-line data from a Phase 2 study for its primary drug candidate targeting NASH came out in March. The company ended the second quarter with nearly $480 million in cash and marketable securities, but has seen insider selling and short interest in the stock.
- 08/10/2023
|
Are Medical Stocks Lagging 89BIO (ETNB) This Year?
- Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.
- 07/07/2023
|
Weight-loss drugs in development aim to replace injections with pills
- Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.
- 06/26/2023
|
89bio shares rise as analysts see improved outlook for NASH treatments
- Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the stock with an outperform rating. The company is focused on developing pegozafermin as a treatment for cardio-metabolic and liver diseases, including non-alcoholic steatohepatitis (NASH), or inflammation caused by buildup of fat in the liver.
- 06/13/2023
|
89BIO (ETNB) Just Overtook the 20-Day Moving Average
- 89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed above the 20-day moving average, suggesting a short-term bullish trend.
- 05/29/2023
|
89bio: Great Prospects After Excellent Phase 2 Data
- ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now.
- 05/28/2023
|
Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know
- The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/05/2023
|
3 Biotech Buyout Targets to Watch
- 89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.
- 04/29/2023
|
Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?
- Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.
- 04/13/2023
|
Ra Capital Management Now Owns 18% of 89bio
- Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).
- 03/31/2023
|
Tech Stocks Are Surging
- The Nasdaq 100 is on a tear
- 03/31/2023
|
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
- NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.
- 03/29/2023
|
89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering
- 89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering appeared first on Pulse 2.0.
- 03/25/2023
|
Why Shares of 89bio Soared This Week
- 89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.
- 03/24/2023
|
89bio's public stock offering upsized by 38%, priced at a 4% discount
- 89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million.
- 03/24/2023
|
89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
- Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.
- 03/23/2023
|
Biotech Stock Surges on Mid-Stage Drug Trial Success
- The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease -- met the main objectives of a mid-stage study.
- 03/22/2023
|
Why Is 89bio (ETNB) Stock Up 34% Today?
- 89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.
- 03/22/2023
|
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
- Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.
- 03/22/2023
|
89bio's stock rallies 48% on new NASH data
- Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution compared to placebo in a Phase 2b clinical trial. The drug, pegozafermin, also demonstrated fibrosis improvement, without worsening of NASH.
- 03/22/2023
|
89Bio: A Promising NASH Innovator
- As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH.
- 03/17/2023
|
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
- The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 03/15/2023
|
4 Best Breakout Stocks to Buy for Superb Returns
- Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.
- 02/24/2023
|
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
- SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.
- 02/21/2023
|
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
- TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
- 02/09/2023
|
Orbimed Advisors Reduces Position in 89bio
- Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of 89bio Inc (ETNB).
- 01/27/2023
|
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?
- 89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 01/17/2023
|
89Bio: Let's Not Give Up Already
- ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action.
- 12/22/2022
|
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
- SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17, 2022 at 11:30 AM ET.
- 10/13/2022
|
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET.
- 09/07/2022
|
89bio: NASH Data Next Year May Change Things For The Better
- ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that.
- 08/23/2022
|
This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations
- In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). SVB Leerink views these results as 'strong' and says they provide a clear win for the company as.
- 07/11/2022
|
89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia
- 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). Hypertriglyceridemia is characterized by high triglycerides (TG) levels, a type of fat, in the bloodstream.
- 06/29/2022
|
89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022
- SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022.
- 06/21/2022
|
89bio Pulls Back With Market — But Could The Stock Soar 250%?
- 89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%. In May, a number of analysts weighed in on 89bio following the biopharmaceutical company printing its first-quarter earnings on May 11.
- 06/10/2022
|
89bio to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the following upcoming investor conferences in May:
- 05/03/2022
|
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
- SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.
- 02/09/2022
|
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021
- Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH
- 10/25/2021
|
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
- SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
- 09/08/2021
|
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
- - Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints -
- 08/02/2021
|
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
- - Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -
- 03/24/2021
|
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
- New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH
- 03/20/2021
|
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
- SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Wednesday, March 17, 2021 at 1:10 p.m. ET.
- 03/11/2021
|
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
- SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.
- 02/24/2021
|
89bio: NASH Drug Developer With Differentiated Profile
- BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated.
- 01/29/2021
|
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
- SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company's Chief Executive Officer, will provide a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.
- 01/04/2021
|
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020
- – Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –
- 11/13/2020
|
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- – Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –
- 11/10/2020
|
IPO Update: Metacrine Seeks $85 Million U.S. IPO
- Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly.
- 09/11/2020
|
89bio (ETNB) Investor Presentation - Slideshow
- The following slide deck was published by 89bio, Inc. in conjunction with this event..
- 08/17/2020
|
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- \- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - \- BIO89-100’s Phase 2 SHTG trial is expected to be initiated in Q3 -SAN FRANCISCO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended June 30, 2020.“We are pleased with the progress we have made with our Phase 1b/2a trial for nonalcoholic steatohepatitis (NASH) and look forward to reporting topline results in late third quarter to early fourth quarter of this year,” said Rohan Palekar, Chief Executive Officer of 89bio. “With our strengthened capital position, we look forward to continuing to advance BIO89-100 and remain on track to initiate the Phase 2 trial in severe hypertriglyceridemia (SHTG) patients during this quarter.” Recent Highlights and Upcoming MilestonesTopline results from the Phase 1b/2a trial of BIO89-100 in NASH are expected in Late Q3 to Early Q4. In April 2020, 89bio closed enrollment in its Phase 1b/2a trial of BIO89-100 in NASH. Topline results are expected in late Q3 to early Q4.Phase 2 trial of BIO89-100 in SHTG on track for initiation in Q3. On May 8, 2020, the Division of Diabetes, Lipid Disorders, and Obesity at the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for BIO89-100 in patients with SHTG. Completed underwritten offering of common stock. In July 2020, 89bio received approximately $78.3 million in net proceeds from an underwritten offering of common stock.Second Quarter 2020 Financial ResultsCash Position. As of June 30, 2020, 89bio had cash, cash equivalents, and short-term investments of $73.9 million.Research and Development (R&D) Expenses. R&D expenses were $8.4 million for the three months ended June 30, 2020, compared to $3.2 million for the three months ended June 30, 2019. The increase in R&D expenses was primarily driven by increases in clinical development, contract manufacturing, pre-clinical development and personnel expenses.General and Administrative (G&A) Expenses. G&A expenses were $3.2 million for the three months ended June 30, 2020, compared to $0.8 million for the three months ended June 30, 2019. The increase in G&A expenses was primarily due to an increase in costs related to professional services and personnel expenses.Net Loss. 89bio reported a net loss of $11.8 million for the three months ended June 30, 2020, compared to a net loss of $15.0 million for the three months ended June 30, 2019. The decrease in net loss is primarily attributable to increased R&D expenses for our programs and increased G&A expenses associated with our becoming a public company offset by a non-recurring charge in 2019 for accounting of preferred stock liability.About BIO89-100 BIO89-100 is a glycoPEGylated analog of FGF21 being developed for the treatment of NASH and the treatment of severe hypertriglyceridemia (SHTG). 89bio has specifically engineered BIO89-100 using a proprietary glycoPEGylation technology designed to prolong the biological activity of native FGF21. In preclinical studies, BIO89-100 demonstrated consistent beneficial effects across a range of endpoints, including hepatic steatosis, injury, and fibrosis. In 89bio’s Phase 1a clinical trial in healthy volunteers, BIO89-100 demonstrated a favorable tolerability profile and dose-proportional pharmacokinetics. BIO89-100 also demonstrated statistically significant improvements in key lipid parameters for two weeks after a single dose, which combined with results from the company’s animal studies supports the potential for weekly or once every two weeks dosing. A proof of concept Phase 1a/2b clinical trial evaluating BIO89-100 in patients with NASH or NAFLD and a high risk of NASH is currently underway and a Phase 2 trial in patients with SHTG is expected to initiate shortly. About 89bio 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH and a Phase 2 trial in patients with SHTG is expected to initiate shortly. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information.Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, 89bio’s expectations regarding plans for its clinical programs and clinical studies. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in 89bio’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond 89bio’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the timing, completion and outcome of 89bio’s Phase 1b/2a proof of concept clinical trial evaluating BIO89-100 in patients with NASH or patients with NAFLD and a high risk of NASH; expectations regarding the timing, completion and outcome of 89bio’s proof of concept Phase 2 clinical trial evaluating BIO89-100 in patients with SHTG; the unpredictable relationship between preclinical study results and clinical study results; the effect of the COVID-19 pandemic on 89bio’s clinical trials and business operations; liquidity and capital resources; and other risks and uncertainties identified in 89bio’s Annual Report on Form 10-Q for the quarter ended March 31, 2020, filed May 13, 2020 with the SEC and other subsequent disclosure documents filed with the SEC. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. 89bio, Inc. Condensed Consolidated Statement of Operations Data (Unaudited) (In thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Operating expenses: Research and development $8,443 $3,165 $16,221 $7,474 General and administrative 3,230 834 6,154 1,357 Total operating expenses 11,673 3,999 22,375 8,831 Loss from operations 11,673 3,999 22,375 8,831 Other expenses (income), net 98 10,968 (59) 10,552 Net loss before tax 11,771 14,967 22,316 19,383 Income tax expense (benefit) — 6 (1) 29 Net loss and comprehensive loss $11,771 $14,973 $22,315 $19,412 Net loss per share, basic and diluted $0.85 $24.50 $1.62 $31.76 Weighted-average shares used to compute net loss per share, basic and diluted 13,797,356 611,226 13,793,544 611,226 89bio, Inc. Condensed Consolidated Balance Sheet Data (Unaudited) (In thousands) June 30, December 31, 2020 2019 Cash, cash equivalents and short-term investments$73,896 $93,335 Total Assets 76,562 95,553 Total current liabilities 6,791 5,609 Total stockholders’ equity 69,771 89,944 Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.comMedia Contact: Lori Rosen LDR Communications 917-553-6808 lori@ldrcommunications.com
- 08/13/2020
|
Why Earnings Season Could Be Great for 89bio (ETNB)
- 89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/11/2020
|
How Much Of 89bio, Inc. (NASDAQ:ETNB) Do Institutions Own?
- Every investor in 89bio, Inc. (NASDAQ:ETNB) should be aware of the most powerful shareholder groups. Generally...
- 08/10/2020
|
89bio to Present at Upcoming Investor Conferences
- SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10 , 2020 at 11:30 AM ET and the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 at 10:00 AM ET. The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. The replay of the webcast will be available on the company’s website.About 89bio89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information. Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.comMedia Contact: Lori Rosen LDR Communications 917-553-6808 lori@ldrcommunications.com
- 08/03/2020
|
13Ds Filings
- Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies
- 07/24/2020
|
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- SAN FRANCISCO, July 13, 2020 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies.
- 07/13/2020
|
89bio (ETNB) Jumps: Stock Rises 6.9%
- 89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 07/10/2020
|
89bio Announces Pricing of Upsized Public Offering of Common Stock
- SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 2,649,600 shares of its common stock at a public offering price of $27.50 per share. In addition, 89bio has granted the underwriters a 30-day option to purchase up to an additional 397,440 shares of common stock at the public offering price, less the underwriting discounts and commissions. BofA Securities, SVB Leerink and RBC Capital Markets are acting as joint book-running managers for the offering.
- 07/08/2020
|
89bio Announces Proposed Public Offering of Common Stock
- SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of 2,200,000 shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 330,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 07/06/2020
|
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H
- 06/06/2020
|
89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
- SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S. Zoth, CPA to its Board of Directors and as Chair of the Audit Committee. A veteran of the biopharmaceutical industry, Ms. Zoth brings more than 35 years of financial and strategic experience to her role. “We are very pleased to have someone of Lota’s caliber join 89bio’s Board of Directors,” said Rohan Palekar, CEO of 89bio.
- 06/04/2020
|
Hedge Funds Dumped 89bio, Inc. (ETNB) During The Crash
- The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- 05/27/2020
|
89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update
- - Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 - - Announces FDA Clearance of BIO89-100 IND Application for SHTG - SAN FRANCISCO, May 13,.
- 05/13/2020
|
89bio to Present at Upcoming Investor Conferences
- SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2020 Virtual Global Healthcare Conference on Thursday May 14, 2020 at 11:00 AM ET and the RBC Capital Markets 2020 Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 3:05 PM ET. 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH.
- 05/08/2020
|
Zacks Investment Research Downgrades 89bio (NASDAQ:ETNB) to Hold
- 89bio (NASDAQ:ETNB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company’s […]
- 04/24/2020
|
22,836 Shares in 89bio (NASDAQ:ETNB) Purchased by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. acquired a new stake in 89bio (NASDAQ:ETNB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,836 shares of the company’s stock, valued at approximately $600,000. Goldman Sachs Group Inc. owned about 0.18% of 89bio as of its […]
- 04/21/2020
|
89bio (NASDAQ:ETNB) Lowered to "Hold" at Zacks Investment Research
- Zacks Investment Research downgraded shares of 89bio (NASDAQ:ETNB) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports. According to Zacks, “89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. […]
- 04/20/2020
|
89bio (NASDAQ:ETNB) Raised to Buy at Zacks Investment Research
- Zacks Investment Research upgraded shares of 89bio (NASDAQ:ETNB) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have $26.00 price objective on the stock. According to Zacks, “89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the […]
- 04/18/2020
|
89bio (ETNB) Receives a Buy from Oppenheimer
- In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on 89bio (ETNB), with a price target of $60.00. The company's shares closed
- 04/13/2020
|
89bio (ETNB) Receives a Buy from Oppenheimer
- In a report released today,
Jay Olson
from Oppenheimer maintained a
Buy
rating on 89bio (
ETNB
–
Research Report
), with a price target of
$60.00
. The company’s shares closed last Monday at $20.96.
According to
TipRanks.com
, Olson is ranked 0 out o
- 04/13/2020
|
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
- SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it closed enrollment in its Phase 1b/2a trial for nonalcoholic steatohepatitis (NASH) with 98% of patients enrolled and has delayed initiation of its severe hypertriglyceridemia (SHTG) trial due to the ongoing COVID-19 pandemic. 89bio also reported new preclinical data confirming BIO89-100’s mechanism of action via potent FGF receptor agonism.
- 04/13/2020
|
89bio (NASDAQ:ETNB) Lowered to Hold at Zacks Investment Research
- Zacks Investment Research lowered shares of 89bio (NASDAQ:ETNB) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead […]
- 04/11/2020
|
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
- Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a
- 04/10/2020
|
Zacks Investment Research Upgrades 89bio (NASDAQ:ETNB) to "Buy"
- 89bio (NASDAQ:ETNB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage presently has a $24.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 13.53% from the company’s current price. […]
- 04/08/2020
|
89bio (ETNB) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB) today and set a price target of $60.00. The company's shares closed last Tuesday at
- 04/01/2020
|
89bio (ETNB) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target
- 04/01/2020
|
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
- SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven Altschuler, M.D., as chairman of its board of directors. “We are very pleased to welcome Steven as chairman of 89bio’s board of directors,” said Greg Grunberg, chair of the nominating and corporate governance committee of 89bio’s board of directors.
- 03/25/2020
|
89bio (ETNB) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB) yesterday. The company's shares closed last Monday at $17.35, close to its 52-week
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
- - BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 -- 89bio, Inc..
- 03/18/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
- SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 at 11:30 AM ET in New York, NY. The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
- 02/21/2020
|
Will 89bio (NASDAQ:ETNB) Spend Its Cash Wisely?
- Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- 02/11/2020
|
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
- 12/19/2019
|
89bio Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- - Upsized Initial Public Offering raises $97.6 million in gross proceeds - - BIO89-100 continues to advance in Phase 1b/2a NASH study - SAN FRANCISCO, Dec. 18, 2019 -- 89bio,.
- 12/18/2019
|
89bio Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- SAN FRANCISCO and HERZLIYA, Israel, Nov. 13, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- 11/13/2019
|
89bio Announces Presentations of BIO89-100 Data at The Liver Meeting® 2019
- SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its.
- 11/11/2019
|
89bio Announces Pricing of Upsized Initial Public Offering
- SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
- 11/11/2019
|
